Streetbeat News

Price Targets

OCX

Needham analyst Mike Matson has reiterated a Buy rating on OncoCyte (NASDAQ:OCX) and maintained a price target of $4.25.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 9:41 am

VSAT

Needham analyst Ryan Koontz maintains a Buy rating on Viasat (NASDAQ:VSAT) but lowers the price target from $28 to $19.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 9:35 am

HOLX

Needham analyst Mike Matson has reiterated a Buy rating on Hologic (NASDAQ:HOLX) and maintained a price target of $90.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 9:31 am

WBA

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) is set to release its Q4 earnings on Oct. 15, with expected earnings of 36 cents per share, down from 67 cents a year ago. Revenue is projected at $35.75 billion, slightly up from $35.42 billion last year. Analysts have recently lowered their price targets for WBA, with Morgan Stanley setting a target of $7, down from $9.

Portfolio Pulse from Avi Kapoor

October 15, 2024 | 7:59 am

IRTC

Analysts have mixed opinions on iRhythm Technologies (NASDAQ:IRTC) with recent ratings showing a shift towards more conservative price targets. The average 12-month price target has decreased by 16.79% to $110.67. Despite positive revenue growth, the company faces challenges with high debt and low returns on equity and assets.

Portfolio Pulse from Benzinga Insights

October 14, 2024 | 9:00 pm

AVDX

AvidXchange Holdings (NASDAQ:AVDX) has been evaluated by 13 analysts over the past three months, with a mix of bullish and bearish outlooks. The average 12-month price target has decreased by 22.79% to $10.23. Analysts have adjusted their ratings and price targets, reflecting a cautious stance on the company's future performance. Despite a 15.33% revenue growth rate, AvidXchange faces challenges with low net margins, ROE, and ROA compared to industry averages.

Portfolio Pulse from Benzinga Insights

October 14, 2024 | 9:00 pm

COTY

In the past three months, 7 analysts have evaluated Coty (NYSE:COTY), showing mixed sentiments. The average 12-month price target is $12.71, slightly down from $12.86. Analysts have adjusted their ratings and price targets, reflecting their views on Coty's market position and financial performance.

Portfolio Pulse from Benzinga Insights

October 14, 2024 | 9:00 pm

PODD

Insulet (NASDAQ:PODD) has received mixed analyst ratings over the past three months, with a majority being bullish. The average 12-month price target has increased by 8.69% to $252.89. Analysts have raised their price targets, reflecting positive sentiment. Insulet's financials show strong revenue growth, high net margin, and efficient asset utilization, but a high debt-to-equity ratio indicates financial risk.

Portfolio Pulse from Benzinga Insights

October 14, 2024 | 8:01 pm

CHDN

Churchill Downs (NASDAQ:CHDN) has received a range of analyst ratings, with a positive shift in price targets over the last three months. Analysts have set an average 12-month price target of $161.82, with a high of $166.00 and a low of $155.00. The company's financial performance is strong, with significant revenue growth, high net margins, and effective debt management.

Portfolio Pulse from Benzinga Insights

October 14, 2024 | 8:01 pm

META

Meta Platforms (NASDAQ:META) has received a mix of bullish and somewhat bullish ratings from 48 analysts, with an average 12-month price target of $617.12, reflecting a 9.2% increase from the previous target. Analysts have raised their price targets, indicating positive sentiment towards Meta's financial performance, including strong revenue growth and efficient cost management.

Portfolio Pulse from Benzinga Insights

October 14, 2024 | 8:00 pm